HomeAbout

TL;DR CNBC


Kate Haviland - TL;DR CNBC

Kate Haviland

Publishing timestamp: 2024-02-28 05:52:01


Summary

Blueprint Medicines CEO, Kate Haviland, achieved FDA approval for the company's treatment of rare disease indolent systemic mastocytosis, expanding the reach of the treatment and increasing revenue. Haviland emphasizes the importance of diversity in the company's success.


Sentiment: POSITIVE

Tickers: BPMC

Keywords: blueprint medicines corpmediabusiness newsexclude from automated curation

Source: https://www.cnbc.com/2024/02/28/kate-haviland-cnbc-changemakers.html


Developed by Leo Phan